Milestones
Aug 2023
Series C financing – Tranche 2 closes
Aug 2023
Enrollment completed for Phase 2 Retinal Detachment study
Apr 2023
First patient dosed in Phase 2 Retinal Detachment study
Mar 2023
Series C financing – Tranche 1 closes
Jan 2023
IND open for ONL1204 Ophthalmic Solution (Phase 2 Retinal Detachment study)
Dec 2022
IND filed for ONL1204 Ophthalmic Solution
Nov 2022
RRD Phase 1 study completed
Nov 2022
GA Phase 1b – Open Label/Dose escalation portion completed
May 2022
First patient dosed in OAG Phase 1b clinical trial
Jan 2022
Series B financing – Tranche 2 closes
Oct 2021
First patient dosed in GA Phase 1b clinical trial (dose escalation phase)
Jul 2021
First patient screened in GA Phase 1b clinical trial
May 2021
Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 3 (100 µg)
Jan 2021
Australian regulatory approval for Phase 1b study in patients with GA secondary to AMD
Dec 2020
Series B financing – Tranche 1 closes
Nov 2020
Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 2 (50 µg)
Mar 2020
Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 1 (25 µg)
Dec 2019
ONL1204 patent issued in US
Oct 2019
First patient dosed, first in human clinical trial in retinal detachment
Oct 2019
Australian regulatory approval for Phase 1 study in patients with retinal detachment
Aug 2019
Convertible note financing
Sep 2018
Convertible note financing
May 2017
Series A financing
Feb 2011
Company formation